Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) has a Wall Street consensus price target of $94.71, based on estimates from 18 covering analysts. With the stock currently trading at $41.10, this represents a potential upside of +130.4%. The company has a market capitalization of $3.93B.
Analyst price targets range from a low of $67.00 to a high of $143.00, representing a 80% spread in expectations. The median target of $87.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CRNX trades at a trailing P/E of -8.3x. Analysts expect EPS to grow +2.8% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CRNX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for CRNX is $94.71, representing 130.4% upside from the current price of $41.1. With 18 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CRNX has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $94.71 implies 130.4% upside from current levels.
CRNX's current price is $41.1 with a consensus target of $94.71 (130.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $143 for CRNX, while the most conservative target is $67. The consensus of $94.71 represents the median expectation. These targets typically reflect 12-month expectations.
CRNX is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CRNX stock forecast based on 18 Wall Street analysts shows a consensus price target of $94.71, with estimates ranging from $67 (bear case) to $143 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CRNX, with a "Buy" consensus rating and $94.71 price target (130.4% upside). 18 of 18 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CRNX analyst price targets range from $67 to $143, a 80% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $94.71 consensus represents the middle ground.